文献速递MDS 与骨髓增殖性肿瘤

HDAC11缺陷破坏骨髓增殖性肿瘤中癌基因诱导的造血

HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms.
PubMed 文献 · Blood · 2020-01-01

该研究通过选择性HDAC抑制剂和基因缺陷小鼠模型,发现HDAC11而非HDAC6是致癌JAK2驱动的MPN细胞及患者样本增殖与存活所必需。Hdac11缺陷可减少异常巨核细胞群体、改善脾结构、减少纤维化并提高MPL W515L-MPN模型小鼠的生存期,提示HDAC11抑制剂是治疗MPN的潜在策略。

要点

  • HDAC11是致癌JAK2驱动MPN细胞增殖与存活的关键分子。
  • Hdac11缺陷可改善MPN小鼠模型的病理特征并延长生存。
  • 选择性HDAC11抑制剂可能成为MPN的替代治疗靶点。

核心结论

  • HDAC11是致癌JAK2驱动的MPN细胞和患者样本增殖与存活所必需的分子。
  • HDAC11抑制剂是治疗MPN的有吸引力的潜在疗法。

研究设计与样本

  • 研究使用新型高选择性HDAC抑制剂和基因缺陷小鼠模型。
  • 利用嵌合骨髓重建评估Hdac11对正常造血干祖细胞分化的影响。
  • 在MPLW515L-MPN小鼠模型中进行原代和二次移植实验。

主要发现

  • HDAC11而非HDAC6是致癌JAK2驱动的MPN细胞及患者样本增殖与存活所必需。
  • HDAC11在原始干细胞中表达不一,主要在谱系定向分化时表达。
  • 基于嵌合骨髓重建,Hdac11对正常稳态造血干祖细胞分化非必需。
  • Hdac11缺陷显著减少MPLW515L-MPN小鼠模型的异常巨核细胞群体、改善脾结构、减少纤维化并提高生存。

临床怎么用

  • HDAC11抑制剂可能用于治疗MPN患者,尤其需替代JAK2抑制剂治疗时。
  • 靶向HDAC11旨在逆转MPN发病机制并控制恶性造血。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Protein acetylation is an important contributor to cancer initiation. Histone deacetylase 6 (HDAC6) controls JAK2 translation and protein stability and has been implicated in JAK2-driven diseases best exemplified by myeloproliferative neoplasms (MPNs). By using novel classes of highly selective HDAC inhibitors and genetically deficient mouse models, we discovered that HDAC11 rather than HDAC6 is necessary for the proliferation and survival of oncogenic JAK2-driven MPN cells and patient samples. Notably, HDAC11 is variably expressed in primitive stem cells and is expressed largely upon lineage commitment. Although Hdac11is dispensable for normal homeostatic hematopoietic stem and progenitor cell differentiation based on chimeric bone marrow reconstitution, Hdac11 deficiency significantly reduced the abnormal megakaryocyte population, improved splenic architecture, reduced fibrosis, and increased survival in the MPLW515L-MPN mouse model during primary and secondary transplantation. Therefore, inhibitors of HDAC11 are an attractive therapy for treating patients with MPN. Although JAK2 inhibitor therapy provides substantial clinical benefit in MPN patients, the identification of alternative therapeutic targets is needed to reverse MPN pathogenesis and control malignant hematopoiesis. This study establishes HDAC11 as a unique type of target molecule that has therapeutic potential in MPN.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Yue L, Sharma V, Horvat NP, et al. HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms. Blood. 2020. PMID: 31750881. doi:10.1182/blood.2019895326

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。